20 results
6-K
EX-99.1
PRFX
PainReform Ltd
26 Jun 24
PainReform Completes Enrollment in the Second Part
4:15pm
, non-opioid pain management solution to patients and healthcare providers. This innovative drug candidate leverages a patented, oil-based, extended
6-K
EX-99.1
PRFX
PainReform Ltd
9 Apr 24
Current report (foreign)
9:07am
the findings: "These IVR study results are a testament to the innovative approach we're taking at PainReform to combat post-surgical pain. By focusing
6-K
EX-99.1
PRFX
PainReform Ltd
29 Jul 22
Investor Presentation July 2022
4:30pm
Market Size Analysis 2019 Report Innovative Formulation / Delivery System Opioid Epidemic Presents Significant Commercial Opportunity Seasoned
20-F
zjwqif2
18 Mar 21
Annual report (foreign)
9:03am
6-K
EX-99.1
jxlh7zxs2 rga
19 Jan 21
Extraordinary General Meeting of Shareholders
4:35pm
6-K
EX-99.1
ghn4yxf5 ib4jeuz
6 Jan 21
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
9:00am
6-K
EX-99.1
evmdbihpy rh
5 Jan 21
Investor Presentation January 2021
4:15pm
424B3
v9l5y
25 Nov 20
Prospectus supplement
11:12am
6-K
EX-99.1
mnqewd
25 Nov 20
PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
10:08am
424B4
tw7pa6lhd
2 Sep 20
Prospectus supplement with pricing info
4:09pm
F-1/A
fbhu2gclxi3yo2a6d
31 Aug 20
Registration statement (foreign) (amended)
6:06am
F-1/A
fvnevck9dyv h19yz6
24 Aug 20
Registration statement (foreign) (amended)
12:15pm
F-1/A
wuhf7hdi6 o4jfqh
10 Aug 20
Registration statement (foreign) (amended)
4:15pm
F-1/A
6ieg0pw9
5 Aug 20
Registration statement (foreign) (amended)
1:26pm
F-1
fto4vd5ji
30 Jun 20
Registration statement (foreign)
5:16pm
DRS/A
t85qxg3 dp25hq1x
2 Jun 20
Draft registration statement (amended)
12:00am
DRS/A
foeupmi2qa
12 May 20
Draft registration statement (amended)
12:00am
DRS
kca75 2p0
3 Feb 20
Draft registration statement
12:00am
- Prev
- 1
- Next